GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises ...

Local medical device companies last month posted fourth quarter results that exceeded analysts’ expectations.Irvine’s Masimo ...

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are ...

As we pass the 1-year anniversary of our controlled launch of iDose TR, I could not be more pleased with our team's execution of our plans for this first-of-its-kind intracameral procedural ...

Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma ...

In other recent news, Glaukos Corporation has reported promising developments regarding its iDose TR product, with clinical trials demonstrating sustained efficacy in reducing intraocular pressure ...

It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical ...